Roche again extends $4.3 billion Spark offer until December 16Christian Fernsby ▼ | December 9, 2019
Roche again extended its offer for shares of gene therapy specialist Spark Therapeutics to December 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.
Acquisition Roche has extended the offering period
Topics: Roche Spark offer
The offer, which was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, December 10, 2019, has been extended until 5:00 p.m., New York City time, on Monday, December 16, 2019, unless it is extended further under the circumstances set forth in the Merger Agreement. All terms and conditions of the Offer shall remain unchanged during the extended period.
The offer was extended to provide additional time for the U.S. Federal Trade Commission and the UK Competition and Markets Authority to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. ■